AETHLON MEDICAL INC

Company Overview

Aethlon Medical Inc. is a clinical-stage healthcare company in the Medical Devices industry focused on developing the Hemopurifier, an extracorporeal device intended to remove harmful extracellular vesicles and enveloped viruses from blood plasma. Its lead program is centered on oncology, where it is running an Australian trial in solid tumor patients receiving anti-PD-1 therapy, while also exploring applications in viral infections and other unmet medical needs. The company remains pre-commercial and depends on regulatory progress, clinical data, and future manufacturing scale-up before it can generate product revenue. It operates with a very small workforce and limited infrastructure, making execution and financing key business priorities.

Executive Compensation Practices

For a clinical-stage medical device company like Aethlon, executive compensation is typically driven more by development milestones than by sales growth, since the company has no commercial revenue yet. Compensation decisions are likely tied to clinical trial execution, regulatory achievements such as IDE or Breakthrough Device progress, patent protection, and capital-raising success, especially given the company’s continued operating losses and need for additional financing. The filing summaries show payroll and related costs changing with executive departures, workforce reductions, bonuses, and severance charges, which suggests management pay and staffing levels are closely linked to cost-control efforts and transition periods. Share-based compensation is likely an important component of total pay, particularly because management must preserve cash while still incentivizing long-duration development work.

Insider Trading Considerations

Insider trading patterns in Healthcare and the Medical Devices industry often reflect clinical trial milestones, regulatory updates, and financing events rather than steady operating performance. For Aethlon, trading activity may be especially sensitive around announcements from the Australian oncology trial, changes in FDA or foreign regulatory paths, warrant inducements, PIPEs, and other equity financings that can materially affect dilution and valuation. Because the company has ongoing cash needs and has disclosed substantial doubt about its ability to fund operations for 12 months, insiders may also trade with heightened caution around financing discussions and material nonpublic information. Researchers should watch for transactions around trial enrollment updates, safety readouts, manufacturing progress, and capital raises, since these are the most likely catalysts for insider buying or selling.